Imo I think it's obvious if you read between the lines that they are going to develop a beer/mj beverage.
Abattis Bioceuticals Corp. (OTCQX: ATTBF) (CSE: ATT) is pleased to announce the following Article:
Looming Legalization has Cannabis Producers Thinking Outside the Dispensary
Baystreet Staff - Friday, January 12, 2018
Looming Legalization has Cannabis Producers Thinking Outside the Dispensary
With legalization on the horizon, Canadian cannabis producers are securing real estate on store shelves—from dispensaries, to pharmacies, to liquor stores.
As it’s said in most commercial undertakings, the most important aspect is “location, location, location.”
This has led to an ambitious staking of ground by cannabis-focused companies, including Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF), Aphria Inc. (TSXV: APH) (OTC: APHQF), Canopy Growth(TSX: WEED) (OTC: TWMJF), and MedReleaf Corp. (TSX: LEAF) (OTC: MEDFF).
In the lead-up to the Canadian government’s lift on marijuana prohibition later this year, clarity over where consumers will be able to purchase products is rising.
Province by province, the concept of cannabis-only dispensaries is still relatively new. As each community wrestles over what kind of access there will be to cannabis, companies are seeking more mainstream nation-wide opportunities to sell their products.
Most recently, Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) announced both a partnership with a major Alliance of Beverage Licensees, securing itself as a featured brand across multiple licensed liquor stores, and the acquisition of a brand that includes vape pens that are already sold in brick and mortar stores.
Aphria Inc. (TSXV: APH) (OTC: APHQF) and MedReleaf Corp. (TSX: LEAF) (OTC: MEDFF) successfully sought an alliance with major pharmacy chain Shoppers Drug Mart.
And Canopy Growth (TSX: WEED) (OTC: TWMJF) made waves by partnering with a major beverage distributor, in anticipation of future sales in cannabis-infused beverages.
Thinking outside the box could give a significant advantage, as the market gears up for the official rollout.
The official list of companies thinking outside the box includes Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF), AphriaInc. (TSXV: APH) (OTC: APHQF), Canopy Growth (TSX: WEED) (OTC: TWMJF), and MedReleaf Corp. (TSX: LEAF) (OTC: MEDFF).
STIRRING CANNABIS WITH BEVERAGES
Easily the biggest cannabis story of 2017 was the allegiance between cannabis and beer. The deal between the world’s largest publicly-traded cannabis company Canopy Growth (TSX: WEED) (OTC: TWMJF) and U.S. drinks company Constellation Brands (NASDAQ: STZ) sent shockwaves across both the cannabis and beer sectors.
Constellation, a beer distributor that owns Corona, saw the potential of the cannabis-infused beverage market, and made a $245 million investment.
Not only did the deal blow up the sector with optimism for a future mainstream acceptance, but it also introduced a natural partnership between both the cannabis and alcohol sectors.
That is why the recent announcements by Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) of an agreement with the Alliance of Beverage Licensees (“ABLE BC”) and the acquisition of Green Tree Therapeutics represent the next form of synergy between cannabis and mainstream distributors.
MAINSTREAM RETAIL ENDORSEMENTS
Closing out 2017, the major Canadian retail/pharmacy chain Shoppers Drug Mart (owned by Loblaw Companies Limited) gave the cannabis sector a definitive stamp of approval—actually, a pair of them.
First was the announcement of a deal with Ontario-based Aphria Inc. (TSXV: APH) (OTC: APHQF), where Aphria-branded medical cannabis products will be sold within the Shoppers Drug Mart chain, online.
Shoppers followed up by inking a deal with another multi-billion-dollar cannabis producer, signing MedReleaf Corp. (TSX: LEAF) (OTC: MEDFF) in the second half of December.
In both cases, the Shoppers Drug Mart endorsement gave shares a price bump.
Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) also made moves to push its retail offerings mainstream with the recent purchase of Green Tree Therapeutics. The acquisition gives Abattis access to over 130 retail stores.
But perhaps the biggest deal that Abattis has made recently was in aligning with the top association of private liquor store outlets—especially given that all signs are pointing to the government of BC utilizing a distribution model that will involve the liquor board.
ABATTIS LEADING WITH EXPERTISE
By aligning with ABLE BC, Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) set itself at the forefront of the commercial cannabis rollout. As part of the deal, Abattis is expected to provide its technical expertise, in terms of quality assurance over dosages, terpene analysis, potency, etc.
Among Abattis’s subsidiaries, and key to the agreement, is its laboratory located in BC, which is a leader in extraction, and testing and analysis.
For consumers and vendors alike, quality assurances are going to be extremely important.
So Abattis’s role beyond supplying products to be sold in these licensed locations will be in educating vendors, and providing testing and inspection issues such as:
- potency and cannabinoid profile;
- microbiological screening;
- pesticide and heavy metal testing;
- terpene analysis;
- and residual solvent testing.
“We foresee this partnership in the cannabis industry a key part of our future. We feel that testing services provided by Abattis will give us the peace of mind that consumers require regarding dosage quality and safety” said Jeff Guignard, Executive Director of ABLE BC.
While the role for Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) with ABLE BC begins in a testing role, it’s possible that future supply deals could be on deck in the future.
Another part of Abattis’s network is that of wholly-owned subsidiary Vergence Naturals, which is equipped to provide future cannabinoid-infused products, including perhaps a line of beverages not unlike those that are expected from Canopy and Constellation.
Vergence just recently added to its portfolio the brand Green Tree Therapeutics, known primarily for its brand of vape pens, and currently already being sold in brick and mortar stores, and over 130 outlets in total.
While not a multi-billion-dollar company like that of Aphria Inc. (TSXV: APH) (OTC: APHQF), Canopy Growth (TSX: WEED) (OTC: TWMJF), and MedReleaf Corp. (TSX: LEAF) (OTC: MEDFF), Abattis has strategically positioned itself as an expert in extraction and testing, as well as cannabinoid-infused product marketing.
There is still plenty of room for entities such as Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) to grow within the cannabis sector that’s still technically in its infancy, as the rollout of legalization finally gets underway.
Please call me if you have any questions. Thank you.
Hugh Oswald
Cell: (604) 838-2855
hugho@shaw.ca
www.abattis.com
